Compare CSTE & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CSTE | RFL |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 54.4M |
| IPO Year | 2012 | N/A |
| Metric | CSTE | RFL |
|---|---|---|
| Price | $1.50 | $1.20 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 471.1K | 94.1K |
| Earning Date | 11-12-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $400,656,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.86 | $1.17 |
| 52 Week High | $5.04 | $3.19 |
| Indicator | CSTE | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 70.95 | 30.40 |
| Support Level | $0.86 | $1.17 |
| Resistance Level | $1.05 | $1.26 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 92.44 | 13.33 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.